89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Nov. 29, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 49,800 shares of the Company's common stock to four new employees (the "Inducement Grants") on November 25, 2024 (the "Grant Date"). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the "Plan"). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
舊金山，2024年11月29日（環球新聞）-- 89bio, Inc.（"公司"或"89bio"）（納斯達克：ETNB）是一家臨牀階段生物製藥公司，專注於開發和商業化創新療法，以治療肝臟和心代謝疾病，今天宣佈公司董事會的薪酬委員會批准向四名新員工授予購買公司普通股的非合格期權，合計49,800股（"誘導授予"），授予日期爲2024年11月25日（"授予日期"）。誘導授予是根據公司2023年誘導計劃（"計劃"）進行的。誘導授予是作爲這些人員與89bio簽訂勞動合同的重要誘因，符合納斯達克上市規則5635(c)(4)。
The Inducement Grants have an exercise price per share that is equal to the closing price of 89bio's common stock on the Grant Date. The Inducement Grants will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the employee's start date, and thereafter the remainder of the shares vest in 12 equal quarterly installments, subject to each employee's continued employment with 89bio through the applicable vesting dates.
誘導授予的行使價格與授予日期時89bio普通股的收盤價相等。誘導授予將在四年內歸屬，員工入職一週年時，25%的股票歸屬，之後其餘股票以12個相等的季度分期歸屬，前提是每位員工在相應的歸屬日期繼續與89bio保持僱傭關係。
About 89bio
89bio is a clinical-stage biopharmaceutical company dedicated to the development of best-in-class therapies for patients with liver and cardiometabolic diseases who lack optimal treatment options. The company is in Phase 3 studies for its lead candidate pegozafermin for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG). Pegozafermin is a specifically engineered, potentially best-in-class fibroblast growth factor 21 (FGF21) analog with unique glycoPEGylated technology that optimizes biological activity through an extended half-life. The company is headquartered in San Francisco. For more information, visit or follow the company on LinkedIn.
關於89bio 89bio是一家專注於爲患有肝臟和代謝性疾病的患者開發最佳療法的臨牀階段生物製藥公司。該公司致力於通過臨牀發展其領先候選藥物pegozafermin，用於治療代謝性功能障礙相關脂肪肝（MASH）和嚴重高三酰甘油血癥（SHTG）。Pegozafermin是一種經過特殊設計的、潛在的最佳成長因數21類似物（FGF21類似物），通過糖基PEG化技術優化生物活性，並具有延長半衰期的特點。公司總部位於舊金山。欲了解更多信息，請訪問www.89bio.com或關注該公司的
89bio是一家臨牀階段生物製藥公司，致力於爲缺乏最佳治療選項的肝臟和心代謝疾病患者開發最佳療法。該公司正爲其主要候選藥物pegozafermin進行三期研究，治療代謝功能障礙相關的脂肪肝炎（MASH）和嚴重高甘油三脂血癥（SHTG）。Pegozafermin是一種專門設計的、潛在的最佳類藥物纖維芽細胞生長因數21（FGF21）類似物，採用獨特的glycoPEGylated技術，通過延長半衰期來優化生物活性。該公司總部位於舊金山。如需更多信息，請訪問或在LinkedIn上關注公司。
Investor Contact:
Annie Chang
89bio, Inc.
investors@89bio.com
投資者聯繫人：
安妮·張
89bio公司
investors@89bio.com
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
PJ Kelleher
生命科學顧問公司
+1-617-430-7579
pkelleher@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
sseapy@realchemistry.com
媒體聯繫人：
Sheryl Seapy
真實化學
sseapy@realchemistry.com
